Informing treatment decisions
Genomics is used to predict drug response. It has allowed for increased sub-typing of tumour types, meaning that targeted treatments can be offered where available – for example, tyrosine kinase inhibitors (TKI) or anti-epidermal growth factor receptor (EGFR) antibodies. The number of drug targets is increasing all the time and it is only a matter of time before more and more treatments are developed.
Clinical teams can in some cases make more informed decisions about the use of radiotherapy and chemotherapy – and the hope is that this will become more common as understanding increases.
The presence of known variations in specific genes can also serve as an indicator of prognosis, and can inform decisions regarding a patient’s care and communication regarding clinical outcomes.